8h agoStocktwits NewsBULLISH 73General
IBRX Breaks Above This Key Resistance — Stock On Track To Record Best Single-Day Gains In 6 Months
ImmunityBio stock climbed over the $10 mark for the first time since March this year.
Archived explainer. For the current picture see today's IBRX page.
Why Is IMMUNITYBIO INC (IBRX) Stock Up Today?
By the Top Tier Newswire AI Desk · September 30, 2026 at 4:02 PM ET · reviewed against 3 wire stories
IMMUNITYBIO INC (IBRX) is up +6.91% in the latest session. Our newswire has captured 3 stories on IBRX across 2 sources in the last 36 hours, with AI sentiment reading bullish (avg 63/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
ImmunityBio Inc. stock surged 6.91% to $9.44 in early trading on Thursday, marking one of the largest single-day gains in six months. The move followed a strong intraday performance that saw the stock briefly surpass the $10 level for the first time since March. The rally appears to be driven by a combination of positive earnings surprises, regulatory progress, and a sharp intraday volume spike.
What Happened
The stock opened at $8.89, a modest 0.7% gap up from the previous close, but quickly gained momentum. By midday, it reached an intraday high of $10.09, fueled by a surge in buying pressure. The stock closed the session at $9.44, with 25.8 million shares traded, 2.3 times the 3-month average. Recent regulatory approvals in the UAE for its lead drug ANKTIVA, including for use in non-small cell lung cancer, have drawn attention to the company’s pipeline. Additionally, Q2 results showed adjusted earnings of -$0.08 per share, which beat expectations, and revenue of $51.24 million, also exceeding forecasts.
What The Data Shows
The stock has gained 11.2% over the last eight sessions, climbing from $8.85 to $9.84. The recent rally has also pushed the stock to a new 52-week high, with 27 fresh 52-week highs recorded on September 30. Despite this, the company remains unprofitable, with a trailing twelve-month EPS of -0.99 and a market cap of $9.0 billion. Retail traders have shown interest, with IBRX gaining 11% in September while many other biotech names declined. Insider transactions show two recent sales totaling $2.7 million, with the most recent filing on July 6, 2026.
What To Watch
Investors should monitor the stock’s volume and price action in the coming sessions to assess the sustainability of the rally. No earnings report is scheduled in the near term, but continued coverage and regulatory developments could influence the stock’s trajectory.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
IBRX by the numbers
Last: $9.44Session: +6.91%7 sessions: +11.19%Coverage: 3 stories / 2 sourcesAI sentiment: 63/100 (bullish)Mkt cap: $9.0B52w: $1.95 to $12.43
The headlines behind the move
8h agoThe FlyBULLISH 63General
ImmunityBio rises 12.3%
21h agoStocktwits NewsNEUTRAL 53General
Biotech Lagged The Broader Market In September — Did Retail Favorites SLS, IBRX, VNDA And IOVA Dodge XBI’s Slump?
IOVA surged 77% and IBRX gained 11%, bucking biotech’s decline, while SLS fell 14% and VNDA slipped 7%.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on IBRX: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier IBRX move explainers: 2026-09-30 · 2026-08-26 · 2026-08-25 · 2026-07-11